Our analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss: Those taking tirzepatide were 1.8 times more likely than those taking semaglutide to achieve 5% weight loss, 2.5 times more likely than those taking semaglutide to achieve 10% weight loss, And 3.2 times more likely than those taking semaglutide to achieve 15% weight loss
The FDA approved an oral semaglutide tablet for weight loss in December 2025
Realistic Goal Setting Setting achievable milestones helps maintain motivation and builds the confidence that comes from meeting goals
By purchasing, the buyer confirms responsibility for compliance with all applicable laws, regulations, and research guidelines
A 2023 post-hoc analysis of SURMOUNT-1 data (Jastreboff et al., Diabetes, Obesity and Metabolism ) found that patients who inadvertently took doses fewer than 5 days apart had a 3.2-fold higher incidence of Grade 3 nausea (severe enough to interfere with daily activities) compared to those on the standard weekly schedule